Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Consulting agrmnt
CC transcript
Director departure
Inv. presentation
|
|
Orexigen Therapeutics, Inc. (OREXQ)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/04/2019 |
4
| BAUPOST GROUP LLC/MA (10% Owner) has filed a Form 4 on Orexigen Therapeutics, Inc.|
Txns:
| Disposed of options to buy
@ $0
Disposed of 5,000,000 options to buy
@ $0
Disposed of 100,000,000 options to buy
@ $0 |
|
| 06/04/2019 |
SC 13D/A
| Baupost Group reports a 0% stake in Orexigen Therapeutics, Inc. |
| 05/31/2019 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 05/23/2019 |
8-K
| Bankruptcy or Receivership, Financial Statements and Exhibits |
| 04/26/2019 |
CT ORDER
| Form CT ORDER - Confidential treatment order: |
| 04/02/2019 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 03/04/2019 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 02/14/2019 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2019 |
SC 13G/A
| Telemetry Investments, L.L.C. reports a 6.4% stake in Orexigen Therapeutics, Inc. |
| 02/12/2019 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/12/2019 |
SC 13G/A
| O'Connor Global Multi-Strategy Alpha Master Ltd reports a 10% stake in Orexigen Therapeutics, Inc. |
| 02/11/2019 |
SC 13G/A
| Man Group plc reports a 0% stake in OREXIGEN THERAPEUTICS, INC. |
| 02/05/2019 |
8-K
| Quarterly results |
| 12/14/2018 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 12/04/2018 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 10/31/2018 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 10/31/2018 |
4
| BAUPOST GROUP LLC/MA (10% Owner) has filed a Form 4 on Orexigen Therapeutics, Inc.|
Txns:
| Sold 650,000 shares
@ $0.01, valued at
$6.5k
Sold 896,339 shares
@ $0.01, valued at
$9k
|
|
| 10/31/2018 |
SC 13D/A
| Baupost Group reports a 37.5% stake in Orexigen Therapeutics, Inc. |
| 10/26/2018 |
4
| BAUPOST GROUP LLC/MA (10% Owner) has filed a Form 4 on Orexigen Therapeutics, Inc.|
Txns:
| Sold 28,000 shares
@ $0.01, valued at
$280
Sold 652,500 shares
@ $0.01, valued at
$6.5k
|
|
| 10/26/2018 |
SC 13D/A
| Baupost Group reports a 37.5% stake in Orexigen Therapeutics, Inc. |
| 10/18/2018 |
CT ORDER
| Form CT ORDER - Confidential treatment order: |
| 10/01/2018 |
8-K
| Quarterly results |
| 07/31/2018 |
8-K
| Acquisition/merger/asset purchase announced|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : July 26, 2018 OREXIGEN THERAPEUTICS, INC. Delaware 001-33415 65-1178822 3344 N. Torrey Pines Ct., Suite 200, La Jolla, CA 92037 Registrant's telephone number, including area code: 875-8600",
"Amendment to the Asset Purchase Agreement, by and between Orexigen Therapeutics, Inc. and Nalpropion Pharmaceuticals, Inc",
"Monthly Operating Report" |
|
| 07/05/2018 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 06/22/2018 |
8-K
| Other Events |
| 06/06/2018 |
8-K
| Quarterly results |
| 06/06/2018 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 04/26/2018 |
4
| BAUPOST GROUP LLC/MA (10% Owner) has filed a Form 4 on Orexigen Therapeutics, Inc.|
Txns:
| Disposed of 16,483,517 options to buy
@ $7.5, valued at
$123.6M
|
|
| 04/26/2018 |
SC 13D/A
| Baupost Group reports a 37.5% stake in Orexigen Therapeutics, Inc. |
| 04/23/2018 |
8-K
| Acquisition/merger/asset purchase announced|
Docs:
|
"FORM 8-K",
"Asset Purchase Agreement, by and between Orexigen Therapeutics, Inc. and Nalpropion Pharmaceuticals, Inc. (Schedules and exhibits have been omitted from this exhibit pursuant to Item 601(b)(2) of Regulation S-K and are not filed herewith. The registrant hereby agrees to furnish a copy of any omitted schedule or exhibits to the U.S. Securities and Exchange Commission upon request.)",
"Key Employee Incentive Plan",
"Bidding Procedures Order, filed with the United States Bankruptcy Court for the District of Delaware on April 23, 2018",
"Orexigen Therapeutics, Inc. Enters Agreement for Sale of Company" |
|
| 04/13/2018 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 04/03/2018 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
| 04/02/2018 |
8-K
| Other Events |
| 03/23/2018 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
|
|
|